MARKET

DBVT

DBVT

DBV Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.850
-0.020
-0.41%
Closed 16:41 05/29 EDT
OPEN
4.690
PREV CLOSE
4.870
HIGH
4.860
LOW
4.650
VOLUME
181.78K
TURNOVER
--
52 WEEK HIGH
13.49
52 WEEK LOW
2.020
MARKET CAP
456.18M
P/E (TTM)
-2.0849
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DBVT stock price target is 11.14 with a high estimate of 29.38 and a low estimate of 3.039.

EPS

DBVT News

More
ZTO, HUYA among premarket losers
Seeking Alpha - Article · 05/21 13:19
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Aurora Cannabis Inc. (NYSE: ACB) shares rose 34.1% to $17.10 in pre-market trading after the company announced plans to acquire CBD platform Reliva for $40 million in Aurora common shares.
Benzinga · 05/21 11:17
61 Biggest Movers From Yesterday
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) shares surged 341.7% to close at $3.40 on Tuesday. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/20 08:50
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) jumped 85.8% to $1.43. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/19 16:48
DVAX, ABUS, ACB and SRNE among midday movers
Seeking Alpha - Article · 05/19 16:45
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020 (Article 223-16 of the General Regulations of the.
GlobeNewswire · 05/12 20:01
32 Stocks Moving in Tuesday's Pre-Market Session
Gainers
Benzinga · 05/12 11:16
Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut Allergies
Seeking Alpha - Article · 05/06 05:02

Industry

Pharmaceuticals
+1.26%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About DBVT

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
More

Webull offers kinds of DBV Technologies SA stock information, including NASDAQ:DBVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DBVT stock news, and many more online research tools to help you make informed decisions.